Immutep Limited logo
Immutep Limited IMMP
$ 2.65 -0.94%

Annual report 2025
added 02-21-2026

report update icon

Immutep Limited Balance Sheet 2011-2026 | IMMP

Annual Balance Sheet Immutep Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -17.4 M -8.93 M -16.8 M -6.46 M -15.9 M -5.25 M -14.2 M -22 M -17 M -45.9 M

Long Term Debt

- - - - - 8.79 M 7.64 M 6.65 M 5.78 M 5.03 M - - - - -

Long Term Debt Current

205 K 234 K 185 K 173 K 208 K 129 K - - - - - - - - -

Total Non Current Liabilities

- - - - - - 10.9 M 9.62 M 5.8 M 5.76 M 1.91 M 14.8 K 5.75 K 10.3 K 4.44 K

Total Liabilities

13.3 M 12.1 M 11 M 8.09 M 8.76 M 13.3 M 16.2 M 13.5 M 8.43 M 7.24 M 6.29 M 2.79 M 3.57 M 4.45 M 2.54 M

Deferred Revenue

- - - - - 1.29 M - - - - - - - - -

Retained Earnings

- - - - - -276 M -262 M -245 M -232 M -222 M -160 M -128 M -115 M -99.7 M -79.8 M

Total Assets

157 M 202 M 147 M 102 M 82 M 46.6 M 40.5 M 47 M 35 M 42.6 M 31 M 25.4 M 32.8 M 41.6 M 57.6 M

Cash and Cash Equivalents

67.4 M 162 M 123 M 80 M 60.6 M 26.3 M 16.6 M 23.5 M 12.2 M 20.9 M - - - - -

Book Value

144 M 190 M 136 M 94.1 M 73.3 M 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M 24.7 M 22.6 M 29.2 M 37.2 M 55.1 M

Total Shareholders Equity

- - - - - 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M - - - - -

All numbers in AUD currency

Quarterly Balance Sheet Immutep Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - 80.1 K - - - 133 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 3.42 M - - - 9.93 M - - - 10.9 M - - - 9.62 M - - - 5.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - 8.76 M - - - 13.3 M - - - 16.2 M - - - 13.5 M - - - 8.43 M - - - 7.24 M - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - -275 M - - - -276 M - - - -262 M - - - -245 M - - - -232 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - - - 82 M - - - 46.6 M - - - 40.5 M - - - 47 M - - - 35 M - - - 42.6 M - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - 60.6 M - - - 26.3 M - - - 16.6 M - - - 23.5 M - - - 12.2 M - - - 20.9 M - - - 6.76 M - - - - - - - - - - - - - - - - -

Book Value

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - 24.7 M - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Balance Sheet is a fundamental financial report of Immutep Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.52 -2.46 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Certara Certara
CERT
$ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA